Japanese pharmaceutical company Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy.
The research – which is being conducted by the research group of Dr Francesco Saverio Tedesco – is being supported through funding of $250,000 from the company's New Frontier Sciences group. Takeda's NFS aims to support innovative, cutting-edge research which could eventually lead to drug discovery and development.
Dr Tedesco's team will focus on the study of muscular regeneration and the potential for stem cell therapies to treat muscular dystrophy, in particular induced pluripotent (iPS) stem cells.
The team is also investigating the potential for treating muscular dystrophy through developing novel gene and cell therapy strategies using artificial human chromosomes and novel biomaterials.
Using this approach, Dr Tedesco hopes to overcome a number of current limitations to developing effective treatments for muscular dystrophies. It is hoped that through the use of these modified stem cells, large quantities of progenitor cells could be produced to be transplanted into a patient's muscle following genetic correction or to be used for drug development platforms.
Importantly, the team will attempt to produce these cells which can be applied more easily in a clinical context, in order to reduce the hurdles that might limit their possible future use in clinical studies.
Through previous work using a mouse model of Duchenne muscular dystrophy, the team has already demonstrated the potential of pre-clinical gene replacement therapy using an artificial human chromosome.
Moreover, in a separate study, Dr Tedesco and his team also demonstrated the potential of genetically corrected iPS cells which had been transplanted into another mouse model of a genetic muscle disorder (limb-girdle muscular dystrophy 2D).
Commenting on the new funding for his research, Dr Tedesco, from the UCL Department of Cell and Developmental Biology, said:
"This funding from Takeda comes at a crucial time for building on our research to develop new and innovative approaches to developing potentially life-changing treatments for muscular dystrophies.
"With Takeda's backing, my team and I will be building on the processes we've already shown to be promising and which could pave the way for the development of novel strategies for both cell therapies and drug discovery in muscle disorders."
Gordon Wong, D.Phil., Head of New Frontier Science at Takeda, added:
"We are delighted to support Dr Tedesco and his team because their ground breaking work has the potential for significant patient benefit."
"That several different strands of their research have already borne fruit was strong evidence for us of the translational potential of Dr Tedesco's research for muscular dystrophies."
For enquiries or to arrange an interview with one of the spokespeople quoted, please contact:
UCL – Henry Rummins
Media Relations Manager (Enterprise)
0207 679 9063/ firstname.lastname@example.org
Takeda – Paul D. Graves
Head of CMSO Communications
About UCL Enterprise
UCL Enterprise provides UCL's structures for engaging with business for commercial and societal benefit. In includes three units: UCL Advances, UCL Business and UCL Consultants, along with corporate partnerships. Together, they provide access to the capabilities and resources of the UCL community to help businesses start, grow and develop.
About UCL (University College London)
Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 27,000 students from almost 140 countries, and around 11,000 employees. Our annual turnover is nearly £1 billion. http://www.ucl.ac.uk | Follow us on Twitter @uclnews
About Takeda New Frontier Sciences
Takeda's New Frontier Science (NFS) group has the mission of finding, developing and integrating innovative foundational technologies into the Takeda drug discovery and development process. NFS provides resources to external innovators through direct funding, access to pharmaceutical drug discovery development resources and collaboration with Takeda scientists and engineers. NFS engages scientists, inventors, or entrepreneurs in collaborative partnerships to advance today's innovations into tomorrow's medicines.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.